June 24, 2023 — Suddenly at the ADA2023 meeting in San Diego, it seems the tides are rolling in to promise more options than ever before for treating obesity. By tides we mean all those drugs targeting the GLP-1 receptors. GLP-1 is shorthand for glucagon-like peptide 1. Most, but not all of these drugs making a splash in San […]
August 26, 2022 — Progress keeps coming in the pharmacotherapy for obesity. This week, Novo Nordisk announced that its new combination therapy of semaglutide and cagrilintide hit all its marks in a 32-week phase 2 study of patients with diabetes and excess weight. The combination – Novo is calling it CagriSema – worked better than either semaglutide or cagrilintide […]
June 24, 2022 — For decades now, Lee Kaplan and Caroline Apovian have led what was known as the Blackburn Course in Obesity Medicine every year at Harvard in June. This year, the name of the course has changed to Obesity Treatment 2022. It has moved to the Dartmouth Geisel School of Medicine, where Richard Rothstein has joined Kaplan […]
November 20, 2021 — Lancet this week published the biggest study yet of cagrilintide – evidence that we’re seeing success in progress with more options for anti-obesity medicines. In a commentary alongside this study, Kishore Gadde and David Allison call this promising news. They point to the advantage of having a new mechanism of action for treating obesity. Also, […]
November 2, 2021 — Monday was quite an opening day for ObesityWeek 2021. Starting with the lived experience, the meeting then moved quickly into some serious science, clinical care, and policy discussions. But one of the most impressive sessions of the day gave us a “tour de force” of future options under development for obesity care. Our friend Mike […]
May 22, 2021 — Anyone following the news on progress with anti-obesity meds might have noticed a rising number of news reports about various “tides” for obesity. Liraglutide is already out there. So is setmelanotide. Semaglutide injection is under review at FDA and approval is possible as early as the middle of this year. Tirzepatide is advancing in clinical […]
